Cargando…
Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease
Dipeptidyl peptidase-4 (DPP-4) is a membrane-bound glycoprotein that acts as a receptor but also exists in a soluble form. It has been recognized as a mediator of inflammation and considered a biomarker in inflammatory bowel disease (IBD). METHODS: We evaluated a prospectively recruited cohort, cons...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954374/ https://www.ncbi.nlm.nih.gov/pubmed/33704099 http://dx.doi.org/10.14309/ctg.0000000000000320 |
_version_ | 1783664067939926016 |
---|---|
author | Pinto-Lopes, Pedro Melo, Francisco Afonso, Joana Pinto-Lopes, Rui Rocha, Cátia Melo, Daniel Macedo, Guilherme Dias, Cláudia Camila Carneiro, Fátima Magro, Fernando |
author_facet | Pinto-Lopes, Pedro Melo, Francisco Afonso, Joana Pinto-Lopes, Rui Rocha, Cátia Melo, Daniel Macedo, Guilherme Dias, Cláudia Camila Carneiro, Fátima Magro, Fernando |
author_sort | Pinto-Lopes, Pedro |
collection | PubMed |
description | Dipeptidyl peptidase-4 (DPP-4) is a membrane-bound glycoprotein that acts as a receptor but also exists in a soluble form. It has been recognized as a mediator of inflammation and considered a biomarker in inflammatory bowel disease (IBD). METHODS: We evaluated a prospectively recruited cohort, consisting of 101 patients with IBD, using validated clinical indexes; 22 patients with ulcerative colitis (UC) underwent endoscopic evaluation. Fecal DPP-4 (fDPP-4) levels were analyzed and correlated with clinical scores, Mayo endoscopic score (in UC patients), serum DPP-4, C-reactive protein, and fecal calprotectin. Immunohistochemical staining for DPP-4 in intestinal biopsies was also performed. RESULTS: When compared with remitters, median fDPP-4 levels were higher in patients with ileal Crohn's disease (CD) (7,584 [1,464–7,816] vs 2,104 [630–2,676] ng/mL, P = 0.015) and lower in patients with UC exhibiting clinical activity (1,213 [559–1,682] vs 7,814 [2,555–7,985] ng/mL, P < 0.001). Patients with UC presenting endoscopic activity also had lower levels than remitters (939 [559–1,420] vs 7,544 [4,531–7,940] ng/mL, P = 0.006). Fecal DPP-4 discriminated clinical activity from remission with areas under the curve of 0.76 (95% confidence interval [CI] 0.58–0.94, P = 0.015) and 0.80 (95% CI 0.68–0.93, P < 0.001) in CD and UC, respectively; it allowed to differentiate endoscopic activity in patients with UC, with areas under the curve of 0.84 (95% CI 0.63–1.00, P = 0.009). Immunohistochemical analysis revealed higher DPP-4 apical expression in UC remitters, but no statistically significant differences were revealed between patients with ileal CD. DISCUSSION: Our results suggest that fDPP-4 can be used as a biomarker of IBD activity, particularly in UC. The expression profiles in intestinal tissue might represent a functional compartmentalization of DPP-4 expression. |
format | Online Article Text |
id | pubmed-7954374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-79543742021-03-15 Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease Pinto-Lopes, Pedro Melo, Francisco Afonso, Joana Pinto-Lopes, Rui Rocha, Cátia Melo, Daniel Macedo, Guilherme Dias, Cláudia Camila Carneiro, Fátima Magro, Fernando Clin Transl Gastroenterol Article Dipeptidyl peptidase-4 (DPP-4) is a membrane-bound glycoprotein that acts as a receptor but also exists in a soluble form. It has been recognized as a mediator of inflammation and considered a biomarker in inflammatory bowel disease (IBD). METHODS: We evaluated a prospectively recruited cohort, consisting of 101 patients with IBD, using validated clinical indexes; 22 patients with ulcerative colitis (UC) underwent endoscopic evaluation. Fecal DPP-4 (fDPP-4) levels were analyzed and correlated with clinical scores, Mayo endoscopic score (in UC patients), serum DPP-4, C-reactive protein, and fecal calprotectin. Immunohistochemical staining for DPP-4 in intestinal biopsies was also performed. RESULTS: When compared with remitters, median fDPP-4 levels were higher in patients with ileal Crohn's disease (CD) (7,584 [1,464–7,816] vs 2,104 [630–2,676] ng/mL, P = 0.015) and lower in patients with UC exhibiting clinical activity (1,213 [559–1,682] vs 7,814 [2,555–7,985] ng/mL, P < 0.001). Patients with UC presenting endoscopic activity also had lower levels than remitters (939 [559–1,420] vs 7,544 [4,531–7,940] ng/mL, P = 0.006). Fecal DPP-4 discriminated clinical activity from remission with areas under the curve of 0.76 (95% confidence interval [CI] 0.58–0.94, P = 0.015) and 0.80 (95% CI 0.68–0.93, P < 0.001) in CD and UC, respectively; it allowed to differentiate endoscopic activity in patients with UC, with areas under the curve of 0.84 (95% CI 0.63–1.00, P = 0.009). Immunohistochemical analysis revealed higher DPP-4 apical expression in UC remitters, but no statistically significant differences were revealed between patients with ileal CD. DISCUSSION: Our results suggest that fDPP-4 can be used as a biomarker of IBD activity, particularly in UC. The expression profiles in intestinal tissue might represent a functional compartmentalization of DPP-4 expression. Wolters Kluwer 2021-03-10 /pmc/articles/PMC7954374/ /pubmed/33704099 http://dx.doi.org/10.14309/ctg.0000000000000320 Text en © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Pinto-Lopes, Pedro Melo, Francisco Afonso, Joana Pinto-Lopes, Rui Rocha, Cátia Melo, Daniel Macedo, Guilherme Dias, Cláudia Camila Carneiro, Fátima Magro, Fernando Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease |
title | Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease |
title_full | Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease |
title_fullStr | Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease |
title_full_unstemmed | Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease |
title_short | Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease |
title_sort | fecal dipeptidyl peptidase-4: an emergent biomarker in inflammatory bowel disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954374/ https://www.ncbi.nlm.nih.gov/pubmed/33704099 http://dx.doi.org/10.14309/ctg.0000000000000320 |
work_keys_str_mv | AT pintolopespedro fecaldipeptidylpeptidase4anemergentbiomarkerininflammatoryboweldisease AT melofrancisco fecaldipeptidylpeptidase4anemergentbiomarkerininflammatoryboweldisease AT afonsojoana fecaldipeptidylpeptidase4anemergentbiomarkerininflammatoryboweldisease AT pintolopesrui fecaldipeptidylpeptidase4anemergentbiomarkerininflammatoryboweldisease AT rochacatia fecaldipeptidylpeptidase4anemergentbiomarkerininflammatoryboweldisease AT melodaniel fecaldipeptidylpeptidase4anemergentbiomarkerininflammatoryboweldisease AT macedoguilherme fecaldipeptidylpeptidase4anemergentbiomarkerininflammatoryboweldisease AT diasclaudiacamila fecaldipeptidylpeptidase4anemergentbiomarkerininflammatoryboweldisease AT carneirofatima fecaldipeptidylpeptidase4anemergentbiomarkerininflammatoryboweldisease AT magrofernando fecaldipeptidylpeptidase4anemergentbiomarkerininflammatoryboweldisease |